STENTYS S.A. announced unaudited revenue results for the third quarter and first nine months ended September 30, 2017. For the first nine months, the company announced revenues were EUR 5,162,400 compared to EUR 5,337,900 for the same period a year ago. For the quarter, the company announced revenues were EUR 1,614,800 compared to EUR 1,693,500 for the same period a year ago. This slight decrease is linked to the end of the commercialization of previous-generation stents (SES /PES), which could not be entirely offset despite a sound increase in sales of the Xposition S stent (increase of 19% in volume and increase of 4% in value).